Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 7/20 | 0.70 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.70 |
| ▸ | PSMB2 | P49721 | 6/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.68 |
| ▸ | LTA4H | P09960 | 9/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3578343 | 0.98 | PSMB1 (0.67) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL3576366 | 0.91 | HRH3 (0.75) | HRH3 | |
| SCHEMBL3578646 | 0.85 | HRH3 (0.90) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL227297 | 0.83 | HRH3 (0.85) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL23724061 | 0.82 | LTA4H (0.87) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL1359959 | 0.82 | ESR1 (0.76) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL1986256 | 0.82 | PSMB1 (0.70) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL25059499 | 0.82 | PSMB1 (0.70) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL227976 | 0.82 | LTA4H (0.87) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL4416554 | 0.82 | PSMB1 (0.70) | PSMB1PSMB5PSMB2HRH3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7749530-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2010075197-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-7692005-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090208557-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-20 | — | — | US | disclosed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208557-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | PSMB1 3258/4885PSMB5 3838/4885PSMB2 2918/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | PSMB1 4003/4885PSMB5 4360/4885PSMB2 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.